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ABSTRACT 
Non-invasive CPAP and HFNC use in children Without Primary Lung 
Pathology: A prospective observational study. 
Abstract 
Aim 
Noninvasive Continuous Positive Airway Pressure (nCPAP) and High Flow Nasal 
Cannula oxygen therapy (HFNC) are non-invasive ventilation (NIV) modalities 
appropriate for children in developing countries. There is minimal literature 
describing nCPAP and HFNC use in children with respiratory compromise 
secondary to non-pulmonary disease.  This study aimed to describe the 
characteristics and outcomes of all children without primary lung pathology, 
who received nCPAP and HFNC during their admission to Red Cross War 
Memorial Children’s Hospital, Cape Town, South Africa. 
Methods: 
This was a prospective observational study of routinely collected data, between 
August 2015 and January 2016.  
Results: 
There were 31 cases of nCPAP and one case of HFNC use in 31 patients (median 
(IQR) age 3.5 (1.8 – 7.6) months.) The majority (n=23; 71.9%) presented with 
primary diarrhoeal disease. There were two deaths (6.5%), 17 (53.1%) 
Paediatric Intensive Care (PICU) admissions, and five (15.6%) cases received 
invasive ventilation (NIV failure). Median (IQR) duration of hospital stay was 
11.50 (6.0 – 17.5) days. On multiple logistic regression there were no 
independent associations with NIV failure.  Lower temperature (OR 0.19; 95% CI 
0.05 – 0.78; p = 0.02) and receiving inotropes (OR 23.05; 95% CI 1.64 – 325.06; p 
= 0.02) were independently associated with PICU admission. 
Conclusions 
nCPAP is used clinically for the management of children with respiratory 
compromise secondary to non-pulmonary illnesses, particularly diarrhoeal 
disease. Larger controlled clinical studies are needed to determine the 
effectiveness and utility of nCPAP in this population. HFNC was not commonly 
used, and this modality requires further investigation in this population. 
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1. LITERATURE REVIEW 
 
Background 
 
Non-invasive ventilation (NIV) 
The term non-invasive ventilation (NIV) refers to respiratory support provided 
by an external interface rather than an invasive airway such as an endotracheal 
tube or tracheostomy (1).  
 
NIV modes include continuous positive airway pressure (nCPAP), bi-level 
positive airways pressure (BiPAP) ventilation, high flow nasal cannula oxygen 
therapy (HFNC), and negative pressure ventilation. NIV may be provided 
through a variety of interfaces including face/nasal masks, mouthpieces, 
cuirasses, helmets, and nasal cannulae (1). NIV is gaining popularity in adult and 
paediatric practice, as it might prevent the need for endotracheal intubation (2) 
and in so doing prevent complications associated with invasive mechanical 
ventilation, including ventilator-associated pneumonia, lung injuries, subglottic 
stenosis and nutritional compromise (3). NIV may also reduce the need for deep 
sedation, thereby maintaining the patient’s cough reflex and allowing more 
effective secretion clearance (4). 
 
A number of adult studies have investigated the use of NIV in various situations, 
including the management of patients with acute exacerbations of chronic 
obstructive pulmonary disease (COPD), asthma, acute lung injury, cardiogenic 
pulmonary oedema and chest trauma (2,5). In a recent review, Walkey and 
Weiner (2013) described NIV use amongst adults in all types of respiratory 
failure, across all diagnostic categories (6).  
 
The “FLORALI” trial was a multi-centre European trial, which randomly assigned 
adult patients (n=313) with non-hypercapnoeic hypoxaemic respiratory failure 
to either HFNC, standard oxygen therapy using a facemask or noninvasive 
positive-pressure ventilation.  Results showed that patients receiving HFNC had 
the lowest intubation rates and the best 90-day survival compared to 
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comparison groups (7).  There are no similar paediatric trials (3). 
 
Despite fewer formal data supporting its use in children (1), NIV has become 
more common in this setting, used for the management of acute and chronic 
respiratory failure, status asthmaticus, hypoventilation syndromes, 
neuromuscular disorders and chronic upper airway obstruction; and to improve 
successful extubation rates (8–10).  NIV is well established for use in the 
neonatal setting for all causes of respiratory distress and early stabilization of 
premature and low birth weight newborns (11). 
 
Most low-income countries cannot provide mechanical ventilator support to 
children, owing to cost, feasibility, resource limitations, staff shortages and 
training levels, amongst others. Therefore, simpler yet effective non-invasive 
methods of providing respiratory support should be considered to improve 
paediatric care outcomes in these settings (12). In this context, both nCPAP and 
HFNC can be provided by stand-alone machines, and adapted for use in low-
resource settings (12). 
 
nCPAP and HFNC use in children beyond the neonatal period has been reported, 
where they have been shown to be clinically effective in the management of a 
range of paediatric respiratory illnesses (13). Both modalities are being used 
clinically for wider indications (12), but there is a paucity of research specifically 
investigating the use of nCPAP and HFNC in the setting of respiratory 
compromise caused by non-pulmonary illnesses.  
 
Continuous positive airway pressure (CPAP)  
nCPAP is a mode of noninvasive ventilation where a preset positive pressure is 
provided continuously, either nasally or via a facemask or mouthpiece (14). 
 
CPAP was initially developed by Dr. George Gregory for use in premature infants 
with Hyaline Membrane Disease (HMD) in the early 1970’s (15). At that time, the 
mortality rate for infants with HMD was over 50%. During this period Harrison 
et al, a group of South African researchers, published their findings that grunting 
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seemed to help infants with HMD to maintain higher saturation levels (16). 
These researchers observed babies who were grunting and noted that their 
condition worsened after tracheal intubation, and improved again once they 
were extubated and allowed to resume grunting. The conclusion was drawn that 
by performing a modified valsalva manoeuvre during grunting, the babies were 
able to maintain their functional residual capacity and improve alveolar 
ventilation. Dr. Gregory used this information and devised a method of providing 
positive pressure via an endotracheal tube.  
 
Measurable effects of CPAP include increased functional residual capacity, de-
creased intrapulmonary shunting, increased tidal volume and decreased airway 
resistance (17). Gregory managed to create these effects with his initial CPAP 
device: an endotracheal tube connected to an Ayres T-piece, which was 
connected to a gas inflow line. Fresh gas was introduced into the system near 
this T-piece, which was connected via corrugate tubing to a reservoir bag. The 
pressure in the system could be adjusted by varying inflow of gas or the degree 
of occlusion at the tail end of the reservoir bag. 
 
Certain complications of CPAP have also been described. These include skin 
erosion at the site of the mask or interface, pneumothorax, abdominal distension, 
upper airway bleeds (1,18) and noise-induced hearing loss (19). 
 
With the use of CPAP, the mortality rate of infants with HMD has dramatically 
declined, and CPAP is used as a lung-protective strategy to prevent long term 
lung damage in preterm infants (20).  CPAP has also been shown to be effective 
in the management of older children with bronchiolitis and other respiratory 
illnesses (21–25) and has become a mainstay of treatment for many of these 
conditions.  
 
There are now numerous delivery systems for nCPAP, some of which are 
straightforward and relatively inexpensive (26). One of these is Bubble CPAP 
where the positive pressure is achieved by keeping the efferent limb of the 
exhale tubing under water and the gas flow adjusted to maintain constant 
 10 
bubbling (12). A study from Ghana (2013) showed that Bubble CPAP is effective 
in decreasing the respiratory rate of children with non-specific respiratory 
distress (27). 
 
Certain centres in resource-limited countries are developing their own bubble 
CPAP devices, sometimes using materials such as recycled plastic bottles, making 
the devices extremely affordable and yet still effective. A study from Malawi (26) 
showed that a stand-alone bubble CPAP device could be developed for one 
fifteenth of the price of the device recently approved by the Food and Drug 
Administration (FDA). 
 
Considering its efficacy in the management of paediatric respiratory illness and 
its cost effectiveness, CPAP represents an important development in child health 
care in the developing world (12). 
 
However, the indications for, and efficacy of CPAP in the management of children 
requiring ventilatory support secondary to primarily non-pulmonary 
pathologies, are currently not clearly defined. 
 
High- flow nasal cannula oxygen therapy (HFNC) 
Heated, humidified, HFNC is a relatively new therapy first described in the early 
1990s (28). It allows the delivery of inspired gas at higher flow rates than 
regular oxygen cannula therapy (1-8 L/min in infants). HFNC flushes dead space 
in the nasopharyngeal cavity allowing for better ventilation and oxygenation; 
provides sufficiently high flow to support inspiration and reduce inspiratory 
work of breathing; and the added humidification eliminates the effects of drying 
and cooling (29). The fraction of inspired oxygen (FiO2) can be adjusted 
according to the patient’s needs and it can also provide some level of CPAP, 
although the exact level cannot always be predicted (12). 
 
HFNC is being used increasingly commonly in neonatal units, either as a step-
down measure from CPAP or as an alternative means of respiratory support in 
the management of HMD (30). The benefits of HFNC are that it is less 
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cumbersome than CPAP, more easily applied, and causes less nasal trauma (31). 
In terms of efficacy, studies have shown no increase in adverse outcomes when 
replacing CPAP with HFNC in the management of HMD (28,31). 
 
HFNC is also being used more frequently in older children beyond the neonatal 
age (3), where it has been shown to be as effective as CPAP in the management of 
bronchiolitis and other respiratory disorders. In a recent retrospective folder 
review by Metge et al (32), HFNC was compared with nCPAP in infants admitted 
to PICU with severe acute bronchiolitis for two subsequent seasons. They 
observed no difference in the length of stay in the PICU, respiratory rate, PCO2, 
FiO2, and duration of oxygen support between the two groups. 
 
Similar to nCPAP, use of HFNC for respiratory support in children without 
primary pulmonary pathology is not well described. 
 
Management of respiratory distress resulting from extra-pulmonary pathology 
Sepsis (resulting in poor oxygenation of tissues with increased oxygen demand) 
and acidosis (with respiratory compensation) are amongst the main 
physiological causes of respiratory distress in children (33).  
 
The paediatric section of the 2012 “Surviving Sepsis Campaign” guidelines for 
treating sepsis and septic shock recommends the use of CPAP or HFNC in the 
initial resuscitation of children with respiratory compromise or hypoxaemia 
associated with sepsis or septic shock (34).  The authors describe how young 
children commonly need early respiratory support in circumstances of severe 
sepsis/septic shock because of their low functional residual capacity, but that 
intubation and ventilation might actually be deleterious in these settings because 
increased intrathoracic pressure can lead to compromised venous return and 
worsening shock. HFNC and CPAP could be used in this setting to increase 
functional residual capacity and reduce work of breathing, allowing for 
establishment of intravenous or intraosseous access for fluid resuscitation and 
peripheral inotrope delivery. By reducing the need for intubation, the use of 
potentially harmful sedative drugs may also be avoided. 
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Despite these recommendations, data supporting the use of nCPAP or HFNC for 
patients in whom the primary pathology is non-respiratory is scarce.  
 
Setting and Current Practice 
Red Cross War Memorial Children’s Hospital (RCWMCH) is a public tertiary and 
secondary level hospital in Cape Town, South Africa. It is the only stand alone, 
specialist children’s hospital dedicated entirely to paediatric care in southern 
Africa. RCWMCH has a total of 275 beds (medical and surgical) of which 15 are 
“High Care” medical beds and 22 are in the paediatric intensive care unit (PICU). 
Currently, all children on nCPAP and HFNC are managed either in ward High 
Care units or in PICU. 
 
An average of 40 000 children per year are seen at RCWMCH, with a large 
proportion of emergency admissions to the High Care units and PICU coming via 
the medical emergency unit (MEU). It is estimated that 360 urgent admissions to 
PICU and 1200 to the high care units are admitted via the MEU. 
 
Because of the highly specialised care available at RCWMCH, a wide variety of 
illnesses are seen, but the majority of patients are admitted with acute infections, 
most commonly respiratory or gastrointestinal, depending on the season. For 
example, in 2013, of 7599 children admitted to the short stay ward at RCWMCH, 
2997 (39.4%) of those presented with acute respiratory infections and 1803 
(23.7%) presented with acute gastroenteritis. A similar proportion would have 
been admitted to higher care settings (MEU records). 
 
At RCWMCH, institutional guidelines recommend the use of nCPAP or HFNC 
(using a stand-alone Bubble-CPAP device for both, with different attachments) as 
the mainstay of care in children presenting in severe respiratory distress, 
particularly those with high respiratory rates and respiratory acidosis on blood 
gas analysis, where intubation and mechanical ventilation are not emergently 
required. Thus, although pulmonary disease remains the primary indication for 
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nCPAP or HFNC, these modalities are also used in the management of children 
with respiratory compromise related to multiple non-pulmonary aetiologies. 
 
In our context, in the summer months a large proportion of patients presenting 
to the emergency department have gastroenteritis and dehydration as their 
presenting complaints, with respiratory compromise occurring as a consequence 
of shock, hypokalaemia or severe metabolic acidosis associated with these 
conditions. Respiratory compromise is also likely in the face of septic shock or 
overwhelming sepsis. It is currently standard practice to consider using 
nCPAP/HFNC for respiratory support in such cases, despite the scarcity of 
supporting evidence.  
 
Literature Review Objective  
The objective of this literature review was to present and synthesise published 
evidence describing the use and benefits/harms of nCPAP or HFNC in children 
with respiratory compromise caused by non-respiratory aetiologies such as 
sepsis, septic shock, electrolyte imbalance and metabolic acidosis.  
 
Search Strategy 
The literature review was conducted using Medline/Pubmed search engines, 
with the final search conducted in November 2016. Search terms included full 
and abbreviated terms for CPAP; HFNC; and non-invasive ventilation with 
modifying terms “children” OR “paediatric”; “sepsis”; and “shock”. 
 
Bibliographies of relevant articles were searched in order to identify as wide a 
range of relevant articles as possible. 
 
Acceptable Studies/Inclusion Criteria 
All research articles written in the English language, investigating infants or 
children receiving nCPAP or HFNC therapy for the management of respiratory 
compromise secondary to non-pulmonary aetiologies, specifically shock/sepsis, 
were included in this review.  
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We excluded adult and neonatal studies, as well as studies focusing on modes of 
NIV other than nCPAP or HFNC. We also excluded studies investigating NIV for 
post-extubation respiratory support. 
 
Considering the paucity of high-level scientific evidence supporting 
nCPAP/HFNC use in this population, methodological aspects were not exclusion 
criteria.  
 
Results and discussion 
Nine studies met the inclusion criteria of this review, and these are summarised 
in Table 1.  
 
Only one article specifically investigated the use of nCPAP in the management of 
respiratory compromise caused by non-pulmonary disease, in the setting of 
sepsis/septic shock (35). In an open prospective randomised controlled study, 
Cam et al (2002) set out to compare the effectiveness of facemask oxygen 
therapy compared to nCPAP therapy in children with Dengue Shock Syndrome 
complicated by respiratory failure.  
 
Dengue Haemorrhagic Fever (DHF) is caused by the Dengue Virus and is 
transmitted by the mosquito Aedes Aegypti. Patients with grade i DHF present 
with early bruising, grade ii with spontaneous bleeding into the skin and 
elsewhere, grade iii with clinical evidence of shock and grade iv with shock so 
severe that blood pressure and pulse cannot be detected. Grades iii and iv are 
termed Dengue Shock Syndrome (DSS). Patients with DSS may develop 
respiratory failure due, at least in part, to increased capillary permeability and 
alveolar-capillary fluid shifts. Previously, patients with DHF/DSS who did not 
respond to oxygen supplementation were intubated and ventilated and this led 
to a number of complications. The study aimed to assess whether the use of 
nCPAP would help to avoid intubation. 
 
The study was carried out in children younger than 15 years with DSS 
complicated by acute respiratory failure, admitted to PICU in Ho Chi Minh City, 
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Vietnam from January 1998 to December 1999.  Acute respiratory failure was 
defined as cyanosis (SaO2 <93%), RR>50 breaths per minute or severe chest 
retraction and nasal flaring. Patients with congenital heart disease, those who 
needed immediate ventilation or who were comatose and those where DSS was 
complicated by pneumonia were excluded. 
 
Thirty-seven patients were randomly assigned to receive either facemask oxygen 
therapy or nCPAP. After 30 mins of treatment, the respiratory rate in the nCPAP 
group decreased significantly (p<0.05) while oxygen saturation and PaO2 
improved in both groups. One patient in the facemask oxygen therapy group did 
not respond to treatment immediately and was given nCPAP, to which there was 
a good response. Subsequently, a further 12 of the remaining 18 assigned to the 
facemask oxygen group, were converted to nCPAP because of treatment failure, 
to which they positively responded. 
 
In the original nCPAP group, four of 18 required invasive ventilation. This 
revealed a significantly higher rate of unresponsiveness to treatment in the 
oxygen mask versus nCPAP group (13/19 vs. 4/18; p<0.01).  These results 
suggest that nCPAP may be more effective than mask-administered 
supplementary oxygen in reducing the need for invasive ventilation in paediatric 
DSS. 
 
Considering that DSS is not endemic to the western Cape region of South Africa, 
the study may not be generalisable to the local population. It is unclear whether 
results from the above study can be extrapolated to the general paediatric 
population with, for example, septic shock or metabolic acidosis. 
 
Whilst use of nCPAP and HFNC for children with primary extra-pulmonary 
conditions has been reported (Table 1), no studies, other than that of Cam et al 
(2002), have specifically reported efficacy and safety of these NIV modalities for 
children with extrapulmonary causes of respiratory distress, suggesting the need 
for further investigation. Instead, studies have included these patients in 
heterogeneous cohorts, and the sample sizes (where known) are generally too 
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small to allow meaningful sub-group analysis. 
 
This study therefore set out to describe current practice of HFNC and nCPAP 
use in the management of children admitted to RCWMCH with primary 
pathologies other than respiratory illness. 
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Table 1: Studies of non-invasive CPAP and HFNC in children whose primary diagnoses include non-pulmonary ones 
 Study Design, Setting, Study 
duration 
Intervention / 
control 
Study Population  Outcomes Conclusions/Comments 
Cam B et al 
(2002) (35) 
Prospective Randomised 
Controlled Trial 
 
PICU of a childrens’ hospital 
in Ho Chi Minh City, Vietnam  
 
January 1998 to December 
1999 
Nasal CPAP vs. 
face-mask 
oxygen 
-Children <15 years (n=37; 
median age 6 years) with 
confirmed Dengue Shock 
Syndrome presenting with 
acute respiratory failure 
 
 
-Significant decrease in RR after 30 
mins in the nCPAP group (p<0.05) 
-13 of the 19 patients in the facemask 
oxygen group deteriorated and were 
converted to nCPAP with good effect 
-4 children in the nCPAP group 
required mechanical ventilation, and 
all 4 died 
-Complications of nCPAP were not 
recorded 
-In children with DSS with 
respiratory failure, nCPAP 
might be useful in the 
management of acute 
respiratory failure. 
-While DSS is not primarily a 
respiratory illness, it remains 
unclear whether these data can 
be extrapolated to children with 
shock/sepsis of other causes. 
Kinikar A et 
al. 
(2011)(36) 
Prospective Observational 
Cohort 
 
Large, tertiary-care public 
teaching hospital in Pune, 
India 
 
August to November 2009 
(during H1N1 “Swine Flu” 
pandemic) 
Nasal Bubble 
CPAP 
-Children 0 -12 years (n=36; 
median age 18 months) 
presenting with respiratory 
distress who were thought to 
have influenza-like illness 
-Children with shock refractory 
to volume and inotropes were 
excluded 
-Cases of ARDS and apnoeas 
were excluded 
- RR, HR and pH all improved after 6 
hours of bubble CPAP (p<0.001,0.015, 
and 0.003 respectively) 
-None of the patients required 
intubation 
-There were no deaths 
-No complications reported 
-Nasal bubble CPAP appeared 
safe and useful in the 
management of children with 
viraemia. 
-All patients had associated lung 
pathology, so results may not be 
applicable to children without 
primary lung pathology. 
-Limited by lack of control 
group. 
Anitha GFS et 
al.  
(2016)(37) 
 
 
 
 
 
 
 
 
 
 
Prospective Observational 
Cohort  
 
Critical Care Unit of a 
government tertiary care 
hospital in India 
 
November 2013 to 
September 2014 
 
 
CPAP using a 
flow-inflating 
device 
-All children (n=214; 78.9% <1 
year of age) between 1 month 
and 12 years admitted to PICU 
who received CPAP  
-Underlying conditions included 
bronchiolitis (30.7%), 
bronchopneumonia (49%), 
septic shock / septicaemia 
(12%), scorpion envenomation 
(2.6%), and other (5.7%) 
-CPAP was successful in 89.7%  
-22 children failed CPAP and were 
intubated 
-Majority of CPAP failures had 
bronchopneumonia with septic shock 
-Of the children with septicaemia, 
CPAP was successful in 23/26 (88%) 
cases 
-Complications occurred in 7.8% 
including pressure sores, abdominal 
distension, and dry oral and 
pharyngeal mucosa 
-Septic shock/septicaemia was 
the primary underlying 
diagnosis in 12% of children 
receiving CPAP.  
-In the majority of these 
patients CPAP was successful 
and well tolerated. 
-The study population, 
sociodemographics and method 
of NIV used are similar to those 
at RCWMCH, hence the study is 
likely generalisable to our 
population. 
-Study limited by lack of control 
group. 
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Wilson PT et 
al (2013)(27) 
 
 
 
 
 
 
 
 
 
Multicentre randomised 
Controlled Trial  
 
Four rural hospitals in 
Ghana 
 
June -November 2011 
 
Nasal CPAP 
immediately or 
one hour after 
presentation. 
-Children aged 3 months to 3 
years  (n=70; mean age 14 
months) presenting to the 
emergency department with 
tachypnea or signs of respiratory 
distress  
-35 of the patients had positive 
Malaria smears 
-Other diagnoses included 
pneumonia, sepsis and severe 
anaemia 
- Study was stopped early, as it 
reached the a priori set efficacy 
boundary. 
-Mean RR in the immediate CPAP 
group fell by 16 bpm (95%; CI 10-
21)  
-No change was seen in the delayed 
CPAP group 
-There were 3 deaths in the 
immediate CPAP group, all in 
children with severe malaria. 
-There were no serious CPAP-related 
adverse events. 
-It is not clear how many 
patients in the study had 
primary respiratory 
diagnoses but a large 
proportion had respiratory 
compromise caused by 
Malaria, which makes this 
study relevant.  
-In these patients, 
immediate CPAP application 
improved RR, and appeared 
to be safe. 
Spentzas T et 
al. 
(2009)(38) 
 
Prospective Observational 
Study  
 
PICU of Le Bonheur 
Childrens’ Medical Centre in 
Memphis, Tennessee, USA 
 
January 2005 - January 2007 
HFNC -Children between 0 and 12 years 
of age (n=46 analysed; median 
age 2.8 years) 
-All patients with respiratory 
distress; but no record of actual 
primary diagnoses 
-22 participants excluded from 
analysis due to incomplete data 
(of these, 2 required mechanical 
ventilation) 
 
-All patients received oxygen via 
nasal prong or face-mask before 
being switched to HFNC 
-Clinical indicators included 
COMFORT scale, RDS score and SaO2 
-All indicators improved on HFNC 
-5 (10.9%) required mechanical 
ventilation 
-Difficult to extrapolate 
results as the study did not 
specify whether the patients 
had primary respiratory 
illnesses or not 
-Study limited by large 
number of exclusions 
(including those with NIV 
failure) 
-HFNC may improve patient 
comfort, respiratory distress 
and SaO2 
-HFNC failure rate was 
approximately 10% 
Kelly GS et al 
(2013)(39) 
Retrospective Cohort 
Review 
 
Two tertiary care paediatric 
emergency departments  
 
June 2011 -September 2012 
HFNC 
 
 
- All children <2 years of age 
(n=498; mean age 7.2 months) 
with all-cause respiratory 
distress, who received HFNC 
within 24 hours of triage were 
included 
-Diagnoses included bronchiolitis, 
pneumonia, status asthmaticus, 
reflux, septicaemia/septic shock 
and croup. 
-42 (8%) cases required intubation 
-Initial RR >90th percentile, pCO2 
>50mmHg and pH<7.3 were 
associated with increased risk of 
HFNC failure 
-Septicaemia/septic shock 
was the underlying 
diagnosis in 16 patients who 
received HFNC. 3 of these 
patients (18.8%) required 
intubation. 
-Study limited by lack of 
control group and 
heterogeneous sample. 
Study Design and settting Type of NIV Study Population Outcomes Conclusions/Comments 
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Brink F et al. 
(2013)(40) 
Prospective Observational 
Study 
 
PICU of Royal Childrens’ 
Hospital, Melbourne, 
Australia 
 
July - November 2011 
HFNC vs 
nasopharyngeal 
CPAP (NP-CPAP) 
-All children who were managed 
with HFNC (n=72; median age 6 
months) or NP-CPAP (n=32; 
median age 5 months) for 
moderate to severe respiratory 
distress. 
-Range of diagnoses included: 
respiratory, pre- and 
postoperative cardiac disease, 
neurological/neuromuscular 
conditions, immunodeficiency 
and other. 
-Escalation of respiratory support 
occurred in 26% of HFNC group and 
18% of the NP-CPAP group 
-The need for escalation could be 
predicted by HR, RR and FiO2 
response within 2 hours 
-Complications of HFNC were 
abdominal distension (n=2) and 
mucosal injury (n=1)   
-nCPAP complications were mucosal 
injury (n=6); pneumothorax (n=2); 
and blocked tubes due to secretions 
(n=2).  
-Although there was no specific 
mention of children with 
sepsis/shock as cause for 
respiratory distress, it is assumed 
that this was the cause of 
respiratory distress in at least 
some of the immunocompromised 
cohort. 
-It is unclear whether HFNC was 
successful in this subgroup or not. 
-There was a trend to better 
tolerance and fewer complications 
of HFNC. 
Schlapbach 
LJ 
(2014)(41) 
 
 
 
 
Retrospective Observational 
Study 
 
Single centre study at PICU 
of Mater Children’s Hospital, 
Brisbane, Australia 
 
January 2005 - December 
2012 
Pre- vs. post 
induction of 
HFNC 
-Children under 2 years (n=793) 
transported into PICU by a 
specialized paediatric retrieval 
team  
-Main causes of respiratory 
distress included: respiratory, 
neuromuscular, cardiac, trauma 
and sepsis 
-Significant decrease in invasive 
ventilation rates on transport after 
induction of HFNC use (49% to 35%; 
p<0.001) 
- No patients retrieved on HFNC 
required intubation during retrieval 
-There were no cases of 
pneumothorax or cardiac arrest in 
those on HFNC. 
-18 children with sepsis as their 
cause of respiratory distress were 
treated with HFNC.  
-The outcomes of this sub-group 
are not reported separately. 
-Introduction of HFNC during inter-
hospital transport was associated 
with reduced rates of invasive 
ventilation during transfers.  
-Limited by historical control 
group and retrospective nature of 
the study. 
Long E et al. 
(2016)(42) 
 
 
 
 
 
 
 
 
Prospective Observational 
study 
 
Royal Childrens’ Hospital, 
Australia 
 
April - September 2013 
 
HFNC -All children presenting to the 
hospital who received HFNC in 
the ED (n=71; median age 9 
months) 
-Most common underlying 
diagnosis was bronchiolitis, other 
conditions were acute LRTI, 
asthma, sepsis, apnoea and 
cardiac disease 
 
 
 -5 (7%) failed HFNC in the ED: 4 
were escalated to nCPAP and 1 was 
intubated  
- After admission to PICU, a further 
16 (23%) needed nCPAP and 7 
(10%) were intubated 
- Overall failure rate was 39% 
-Adverse events in ED: abdominal 
distension (n=3); severe 
air leak progressing to requiring 
intubation (n=1) 
-Included only one patient who 
required HFNC for sepsis, all others 
had respiratory disease. HFNC use 
in this patient was successful. 
-Limited by lack of control group 
PICU=paediatric intensive care unit; CPAP=continuous positive airways pressure; RR=respiratory rate; DSS=Dengue Shock Syndrome; ARDS=Acute Respiratory Distress Syndrome; 
HR= heart rate; RDS=respiratory distress syndrome; NP-CPAP=nasopharyngeal CPAP; ED=emergency department 
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Abstract 
Aim 
Noninvasive Continuous Positive Airway Pressure (nCPAP) and High Flow Nasal 
Cannula oxygen therapy (HFNC) are non-invasive ventilation (NIV) modalities 
appropriate for children in developing countries. There is minimal literature 
describing nCPAP and HFNC use in children with respiratory compromise 
secondary to non-pulmonary disease. This study aimed to describe the 
characteristics and outcomes of all children without primary lung pathology, 
who received nCPAP and HFNC during their admission to Red Cross War 
Memorial Children’s Hospital, Cape Town, South Africa. 
 
Methods: 
This was a prospective observational study of routinely collected data, between 
August 2015 and January 2016.  
 
Results: 
There were 31 cases of nCPAP and one case of HFNC use in 31 patients (median 
(IQR) age 3.5 (1.8 – 7.6) months.) The majority (n=23; 71.9%) presented with 
primary diarrhoeal disease. There were two deaths (6.5%), 17 (53.1%) PICU 
admissions, and five (15.6%) cases received invasive ventilation (NIV failure). 
Median (IQR) duration of hospital stay was 11.50 (6.0 – 17.5) days. On multiple 
logistic regression there were no independent associations with NIV failure.  
Lower temperature (OR 0.19; 95% CI 0.05 – 0.78; p = 0.02) and receiving 
inotropes (OR 23.05; 95% CI 1.64 – 325.06; p = 0.02) were independently 
associated with PICU admission. 
 
Conclusions 
nCPAP is used clinically for the management of children with respiratory 
compromise secondary to non-pulmonary illnesses, particularly diarrhoeal 
disease. Larger controlled clinical studies are needed to determine the 
effectiveness and utility of nCPAP in this population. HFNC was not commonly 
used, and this modality requires further investigation in this population. 
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What is already known on this topic: 
 Non-invasive ventilation has become an evidence-based practice for 
certain conditions in adults and neonates 
 In infants and older children with respiratory illnesses, NIV may prevent 
the need for invasive ventilation  
 Bubble nCPAP and HFNC are effective and cheap to administer, making 
them important health interventions in developing countries 
 
What this paper adds: 
 This paper describes the use of nCPAP and HFNC in children with 
respiratory compromise caused by non-pulmonary illnesses, most 
commonly diarrhoeal disease 
 Independent predictors of the need for intensive care in these children 
were identified. 
 
Introduction 
Non-invasive ventilation (NIV) refers to respiratory support provided by an 
external interface rather than an invasive airway such as an endotracheal tube or 
tracheostomy (1). This form of ventilation is gaining popularity in adult and 
paediatric practice, as it might prevent the need for endotracheal intubation (2) 
and in so doing prevent complications associated with invasive mechanical 
ventilation (3).  
 
NIV has been well described in the adult population (2,4), and is used in the 
management of adult respiratory failure, across all diagnostic categories (5). 
Compared to other forms of NIV in adults, High Flow Nasal Cannula oxygen 
therapy (HFNC) is associated with the lowest intubation rates and the best 90-
day survival rate (6).  NIV is also well established for use in the neonatal setting, 
in the management of all-cause respiratory distress and for the early 
stabilization of premature and low birth weight newborns (7). Despite fewer 
formal data supporting its use in infants and older children (1), NIV is becoming 
more popular in in this setting, commonly used in the management of acute and 
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chronic respiratory failure; status asthmaticus; hypoventilation syndromes; 
neuromuscular disorders and chronic upper airway obstruction; as well as the 
prevention of extubation failure (8–10).   
 
In low and middle income countries, where mechanical ventilatory support 
cannot be provided to the majority of children owing to resource limitations, 
simple yet effective non-invasive methods of providing respiratory support 
should be considered to optimise clinical paediatric outcomes (11). In this 
context, both noninvasive continuous positive airways pressure (nCPAP) and 
HFNC can be provided by stand-alone machines, and have been adapted for use 
in low-resource settings (11). 
 
nCPAP has been shown to be effective in the management of older children with 
bronchiolitis and other respiratory illnesses (12–16) and has become a mainstay 
of treatment for many of these conditions. HFNC is also being used more 
frequently in older children (3), where it has been shown to be as effective as 
nCPAP (17).  
 
nCPAP and HFNC are also recommended in the initial resuscitation of children 
with respiratory compromise or hypoxaemia associated with sepsis or septic 
shock (18). Despite these recommendations, data supporting the use of nCPAP or 
HFNC for patients in whom the primary pathology is non-pulmonary are scarce. 
We found only one article which specifically investigated the use of nCPAP in the 
management of respiratory compromise caused by non-pulmonary disease, this 
in the setting of Dengue shock syndrome (19). Other studies have included 
heterogeneous populations, with sample sizes too small to allow meaningful sub-
group analyses (20–27). To the best of our knowledge no other studies have 
systematically evaluated the use of nCPAP or HFNC therapy specifically in 
children with non-pulmonary causes of respiratory compromise.  
 
This study therefore aimed to describe the use of HFNC and nCPAP in the 
management of children admitted to Red Cross War Memorial Children’s 
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Hospital (RCWMCH), Cape Town, South Africa, with primary pathologies other 
than respiratory illness. 
 
Setting  
RCWMCH is a public tertiary and secondary level hospital in Cape Town, South 
Africa. It is the only stand alone, specialist children’s hospital dedicated entirely 
to paediatric care in sub-Saharan Africa. RCWMCH has a total of 275 beds 
(medical and surgical) of which 15 are “High Care” medical beds and 22 are in 
the paediatric intensive care unit (PICU). Currently, children on nCPAP and HFNC 
are managed both in high care ward units and in PICU. 
 
Approximately 40 000 children per year are managed at RCWMCH. It is 
estimated that annually 360 children are admitted to PICU and 1200 to high care 
units via the medical emergency unit (MEU) (MEU records). Because of the 
highly specialised care available at RCWMCH, patients present with a wide 
variety of illnesses, but the majority of patients are admitted with acute 
infections, most commonly respiratory or gastrointestinal, depending on the 
season.  
 
At RCWMCH, institutional guidelines recommend the use of nCPAP or HFNC, 
using a stand-alone Bubble-nCPAP device (Fisher & Paykel Healthcare, Auckland, 
New Zealand) as the standard of care in children presenting in severe 
respiratory distress where intubation and mechanical ventilation is not 
emergently required. The interface standardly used for nCPAP is the F&P 
FlexiTrunk™ midline interface and nasal prongs, whilst appropriately sized 
Pediatric Oxygen Therapy Nasal Cannulae are used for HFNC (Both Fisher & 
Paykel Healthcare, Auckland, New Zealand). Although pulmonary disease 
remains the primary indication for nCPAP or HFNC, these modalities are also 
used in the management of children with respiratory compromise related to 
multiple non-pulmonary aetiologies. 
 
In our context, in the summer months, a large proportion of patients present to 
the emergency department with gastroenteritis and dehydration as their 
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primary illness, with respiratory compromise occurring as a consequence of 
shock, hypokalaemia or severe metabolic acidosis. Respiratory compromise is 
also common in the face of septic shock or overwhelming sepsis. It is currently 
standard practice to consider using nCPAP/HFNC for respiratory support in such 
cases, despite the scarcity of supporting evidence. 
 
Study Design and Period 
This was a prospective, single centre, observational study of routinely collected 
data between August 2015 and January 2016. 
 
Participants 
All children between 0 and 12 years who received nCPAP or HFNC as part of 
standard respiratory care, and in whom respiratory compromise was not caused 
by primary lung pathology, were included in the study. 
 
Neonates requiring respiratory support for HMD or other diseases of the 
newborn period, children receiving chronic/home-based nCPAP/HFNC, and 
children with cardiogenic pulmonary oedema were excluded from the study. 
 
Ethics Approval 
Permission to conduct the study was obtained from the University of Cape 
Town’s Faculty of Health Sciences Human Research Ethics Committee [Appendix 
Pg 65-66] and written informed consent was obtained from parents/legal 
guardians. The study adhered to the provisions of the Declaration of Helsinki 
(2013)(28). 
 
Method 
MEU admissions were reviewed daily by the researcher to identify eligible 
patients. Patients receiving nCPAP/HFNC therapy in the medical wards or PICU 
were screened for eligibility daily by the same researcher. Parents/ caregivers 
were approached for consent after admission of their child but prior to the 
collection of data from the files. All parents approached gave consent. 
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Routinely collected admission data was prospectively collected from clinical 
folders on all eligible patients, using a standardised data collection form. 
Outcome data were collected at discharge or after death from digital or paper-
based hospital records. 
 
Statistical Analysis 
Data were entered into an Excel spreadsheet and appropriate parametric or 
nonparametric descriptive analyses were conducted using Statistica version 12 
(StaSoft Inc, Tulsa, USA), after testing for normality (Shapiro Wilks W test). 
Comparative statistics were conducted using Mann-Whitney U tests, using failure 
of nCPAP/HFNC (progression to intubation and invasive ventilation) and PICU 
admission as categorical primary and secondary outcome measures. Mortality 
was a further planned secondary outcome measure, but owing to small numbers 
(n=2) was not analysed further. Data found to be associated with the primary 
and secondary outcomes on univariate analysis (p < 0.05) were entered into 
backward stepwise logistic regression models to determine independent 
predictive factors. A significance level of p< 0.05 was used for this study. 
 
Results 
There were 31 cases of nCPAP and one case of HFNC use in 31 patients (median 
(interquartile range, IQR) age 3.5 (1.8 – 7.6) months; 50% male).  
 
Twenty-three of the 32 cases (71.9%) presented with respiratory distress 
secondary to diarrhoeal disease or complications thereof. Of these, 18 (78.3%) 
were shocked and 12 (52.2%) required inotropic support.  One patient was 
admitted twice, on both occasions with shock and respiratory compromise 
associated with diarrhoeal disease. Seven of the 32 cases (21.9%) were admitted 
with septicaemia/septic shock. Four of the seven were shocked and only one 
required inotropes.  One child was admitted with acute liver failure and 
metabolic acidosis with respiratory compensation and increased work of 
breathing and one with meningitis who was lethargic and required respiratory 
support. Both were shocked and initiated on nCPAP therapy. A total of 24 (75%) 
cases were shocked on admission. 
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13 of the 31 patients (41.9%) were Human Immunodeficiency Virus (HIV) 
exposed but uninfected, and three (9.7%) were HIV infected.  
 
The only patient who was treated with HFNC had diarrhoeal disease and 
Salmonella sepsis (without shock). HFNC was initiated on the basis of the patient 
clinically tiring.  
 
One (3.2%) complication of NIV was documented, of nasal skin trauma related to 
pressure caused by the nCPAP interface. 
 
Primary outcome:  
Five (15.6%) patients failed NIV and were intubated and mechanically 
ventilated. These included the patient with acute liver failure, two cases with 
diarrhoeal disease and two cases with septicaemia. 
 
Secondary outcomes:  
Seventeen (53.1%) cases required ICU admission, with diarrhoeal disease 
(n=13); septicaemia (n=3); and acute liver failure (n=1).  
 
Two (6.5%) patients died. Both deaths occurred in children who presented with 
diarrhoeal disease and comorbid chronic illness. One patient had neuroblastoma 
and previous ventriculo-peritoneal shunt. He demised in the MEU before 
admission to High Care or PICU but was given fluid boluses and started on 
nCPAP and inotropes as part of his emergency management. The second patient 
had congenital Haemolytic Uraemic Syndrome (HUS) with chronic kidney 
disease and demised after a protracted hospital stay. 
Table 1 presents univariate analyses of baseline characteristics and outcomes 
between primary and secondary outcome measures. Although patients who 
failed NIV had lower presentation SaO2 on univariate analysis (Table 1), this 
association was not present on multiple logistic regression [OR 1.02; 95% CI 
0.97 – 1.08; p = 0.6]. Lower temperature (adjusted OR 0.19; 95% CI 0.05 – 0.78; p 
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= 0.02) and receipt of inotropes (OR 23.05; 95% CI 1.64 – 325.06; p = 0.02) were 
independently associated with PICU admission.  
 
Positive blood cultures within the first three days were obtained in three (9.3%) 
cases: one case each of Pseudomonas aeruginosa and coagulase negative 
Staphylococcus aureus in patients who presented with diarrhoeal disease and 
one case of  Streptococcus pneumoniae in a patient with septicaemia. The 
coagulase negative Staphylococcus aureus was considered likely to have been a 
contaminant. 
 
Two of the children with septicaemia had nasopharyngeal aspirate (NPA) 
specimens sent for respiratory viral panel analysis. These were both positive for 
respiratory syncytial virus (RSV) A and Adenovirus respectively. Four of the 
children with diarrhoeal disease had NPAs sent of which two were positive for 
both Adenovirus and Rhinovirus, and two were negative. The patient with acute 
liver failure had a negative NPA. 
 
Discussion 
To the best of our knowledge, this is the first study to systematically describe the 
clinical use of nCPAP and HFNC in children admitted to hospital with respiratory 
compromise associated with primarily non-respiratory disease. HFNC was used 
in only one case, for reasons that are unclear, and this NIV modality therefore 
requires further research in this population. 
 
The vast majority (71.9%) of children receiving nCPAP/HFNC in this study 
presented with diarrhoeal disease (many with associated shock) requiring 
respiratory support. Globally, diarrhoeal disease is one of the leading causes of 
death in children under five years of age, responsible for more child deaths than 
AIDS, Malaria and Measles combined (29). There is a particularly high burden of 
diarrhoeal disease in South Africa (30) , where an estimated 10 109 000 (54%) 
children live below the poverty line of R671 (approximately $48) per month. In the 
Western Cape province, in 2013, approximately 486 000 (26%) children were 
living in income-poor households (31). Diarrhoeal disease is responsible for 20% 
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of child deaths under five years of age in South Africa (32). 
 
Considering the burden of disease, limited PICU resources, and poor access to 
paediatric healthcare centres in South Africa (33); there is a need to identify safe, 
effective, and affordable means of providing respiratory support to children with 
complications of diarrhoeal disease, sepsis, and other conditions outside the 
PICU setting. In this context, nCPAP and HFNC require further study, but are 
promising in terms of availability and affordability. A study from Malawi (34) 
showed that a stand-alone bubble nCPAP device could be developed for one 
fifteenth of the price of the device recently approved by the Food and Drug 
Administration (FDA). In a recently published study conducted in Cape Town, 
South Africa, ventilatory management was identified as an important modifiable 
factor in the initial management of critically ill children presenting to city health 
clinics, which could impact on morbidity (33). nCPAP and HFNC could feasibly be 
implemented at such centres. Although no definitive conclusions can be made on 
the basis of this study, and more research is needed, it is notable that 47% of 
children were spared PICU admission after nCPAP/HFNC therapy was provided 
in the ward high care units. This finding may have important implications for low 
resourced countries with little access to high-level PICU care. 
 
The paediatric section of the 2012 “Surviving Sepsis Campaign” guidelines for 
treating sepsis and septic shock recommends the use of nCPAP or HFNC in the 
initial resuscitation of children with respiratory compromise or hypoxaemia 
associated with sepsis or septic shock (18). Young children with severe sepsis or 
shock commonly require early respiratory support owing to low functional 
residual capacity. However, intubation and ventilation in these circumstances 
may cause harm by increasing intrathoracic pressure with resulting 
compromised venous return and worsening shock. HFNC and nCPAP could be 
effective in this setting, by increasing functional residual capacity and reducing 
work of breathing, thereby allowing for establishment of intravenous or 
intraosseous access for fluid resuscitation and peripheral inotrope delivery.(18) 
By reducing the need for intubation, the use of potentially harmful sedative 
drugs may also be avoided. 
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The 15.6% NIV failure rate is within the range (11.5% and 19%) described 
previously in children with sepsis (21,24). In a study investigating nCPAP use in 
critically ill children in a resource limited setting, Anitha et al (21) found 
associated shock to be a risk factor for nCPAP failure, while Kelly et al (24) found 
that those who failed NIV had presented with a higher venous pCO2, higher initial 
RR, and a lower venous pH than those in whom NIV was successful. On 
univariate analysis, Mayordomo et al (35) found that smaller children were at 
higher risk of NIV failure. We were, however, unable to identify any predictive 
factors for NIV failure on the basis of such admission characteristics 
 
The complication rate in this study was low, at 3%, but skin breakdown and 
pressure ulcers have been previously reported as complications of nCPAP (1,35). 
Therefore care must be taken in applying the interface and frequently checking 
for pressure areas. Other complications of both nCPAP and HFNC which have 
been described include pneumothorax and other air leak syndromes (27), 
abdominal distension, upper airway bleeds (1,35,36) and noise-induced hearing 
loss (37). 
 
In our setting, PICU admission is largely dependent on resources and availability 
of PICU beds, therefore not being admitted to PICU does not necessarily always 
reflect lower acuity of illness. However, we found that lower admission body 
temperature and the receipt of inotropes were independent predictors of PICU 
admission, possibly reflecting higher severity of illness in these patients. Studies 
have shown that scoring systems such as the “Pediatric Early Warning Systems”/ 
PEWS”, which include assessment of temperature and blood pressure, may be 
able to predict the need for a higher level of care when they are used in the 
emergency department (38). Our findings support the use of such scoring 
systems to timeously recognise children who may require PICU admission and 
increased levels of support. 
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Limitations 
This was a single-centre study with a small sample size, and no control group, 
which constitute the major limitations of this study. The actual prevalence of 
HFNC/nCPAP in this population cannot therefore be determined. However, the 
sample size is comparable to that of previous studies of NIV use in children 
(19,20,22). Randomized controlled trials with larger, homogeneous study 
populations are needed to establish the safety and efficacy of nCPAP and HFNC in 
the management of children with diarrhoeal disease, and other non-pulmonary 
diseases.  
 
Having had only one researcher recruiting patients throughout the study period, 
there is a possibility that eligible patients might have been missed. It is possible 
that children had co-existing, but undiagnosed, respiratory pathology, which 
might have confounded the results of this study and contributed to patients’ 
respiratory distress. The positive viral screens in a number of respiratory 
specimens support this suggestion. However, it is not clear how many identified 
viruses represent colonization or asymptomatic carriage. Respiratory tract 
secretions were not taken on all patients in a standardised fashion, and no 
conclusions can therefore be made in this regard.  
 
Conclusion 
nCPAP is used clinically for the management of children with respiratory 
compromise secondary to non-pulmonary illnesses, particularly diarrhoeal 
disease. In the majority of cases intubation and mechanical ventilation were 
avoided.  Larger controlled clinical studies are needed to determine the 
effectiveness and utility of nCPAP in this population. HFNC was not commonly 
used, and this modality requires further investigation in this setting. 
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Tables 
Table 1: Baseline characteristics and outcomes (n=32 cases) 
 
Variable 
All cases 
(n=32) 
Admitted 
to PICU 
(n=17) 
Not 
admitted 
to PICU 
(n=14) 
Intubated 
(n=5) 
Not 
intubated 
(n=27) 
P (Not 
admitted 
to PICU vs. 
PICU) 
P 
(intubated 
vs not 
intubated)  
Age (months) 
(median [IQR]) 
3.45 (1.8 – 
7.6) 
2.27 (1.8 – 
3.9) 
6.12 (1.03 
– 10.3) 
1.8 (1.73 – 
1.80) 
5.27 (1.93 
– 10.0) 
0.26 0.12 
Gender M:F 16:16 9:9 7:7 2:3 14:13 1 0.6 
HIV exposed n (%) 14 (43.75) 7 7 2 12 0.6 0.8 
HIV infected 3 (9.38) 0 3 0 3 0.2 0.96 
Shocked 24 (75.0) 16 8 4 20 0.04 0.8 
Received CPAP 31 (96.88) 17 13 5 26 0.9 0.4 
Received HFNC 1 (3.13) 0 1 0 1 
Received fluid bolus 26 (81.25) 16 10 5 21 0.20 0.4 
Total fluid bolus 
(ml/kg) (median 
[IQR]) 
32.5 (20.0 
– 60.0) 
40.0 (20.0 
– 60.0) 
25.0 (10.0 
– 40.0) 
20.0 (10.0 
– 40.0) 
35.0 (20 – 
60) 
0.36 0.42 
Received inotropes 13 (40.63) 11 2 1 12 0.02 0.6 
PCT (mcg/L) 
(median [IQR]) n=15 
14.25 (4.3 
– 35.0) 
10.48 (4.3 
– 35.0) 
19.1 (19.1 
– 19.1) 
(n=1) 
4.9 (1.98 – 
6.7) 
19.55 (4.4 
– 35.0) 
1 0.30 
Creatinine(micromol
/L) (median [IQR]) 
56.5 (29.5 
– 114.0) 
90.0 (50.0 
– 125.0) 
38.0 (22.0 
– 74.0) 
58.0 (35.0 
– 90.0) 
55.0 (26 – 
115) 
0.02 1 
Urea (mmol/L) 
(Median [IQR]) 
6.4 (3.5 – 
12.9) 
10.3 (4.7 – 
16.2) 
3.9 (3.0 – 
8.6) 
10.6 (4.7 – 
11.1) 
6.3 (3.3 – 
13.5) 
0.01 0.42 
Cl (mmol/L) (Median 
[IQR]) 
115.0 
(102.0 – 
127.0) 
126.0 
(104.0 – 
139.0) 
106.5 
(102.0 – 
120.0) 
114.0 
(106.0 – 
127.0) 
116.0 (102 
– 126) 
0.10 0.50 
K (mmol/L) (median 
[IQRT]) 
4.0 (2.4 – 
4.8) 
4.6 (2.2 – 
4.9) 
3.4 (2.7 – 
4.5) 
4.6 (4.5 – 
4.6) 
3.9 (2.4 – 
4.9) 
0.49 0.66 
Na (mmol/L) 
(median [IQR]) 
139.0 
(134.0 – 
145.5) 
140.0 
(136.0 – 
153.0) 
136.0 (133 
– 143) 
140.0 (134 
– 144) 
139 (133 – 
146) 
0.12 0.84 
CRP (mg/L) (median 
[IQR] 
14.3 (7.15 
– 59.0) 
12.0 (7.0 – 
57.0) 
14.3 (8.85 
– 62.95) 
17.35 
(12.05 – 
39.35) 
12.95 
(6.85 – 
62.95) 
0.71 0.72 
Platelets x 109/L 
(mean ± SD) 
397.38 ± 
192.32 
392.94 ± 
160.57 
419.5 ± 
227.35 
405.2 ± 
166.62 
395.93 ± 
199.54 
0.71 0.92 
Hb (g/dL) (mean ± 
SD) 
9.85 ± 2.96 9.9 ±2.66 9.88 ±3.46 8.92 ± 1.71 10.02 
±3.13 
0.98 0.45 
WCC x 109/L (median 
[IQR]) 
17.40 
(11.32 – 
25.56) 
17.8 
(14.66 – 
23.0) 
14.3 (9.39 
– 26.6) 
17.8 (17.6 
– 40.0) 
15.4 
(10.74 – 
24.51) 
0.24 0.31 
Lactate (median 
[IQR]) 
2.2 (1.6 – 
6.8) 
3.2 (2.0 – 
8.0) 
1.85 (1.0 – 
2.7) 
5.25 (1.75 
– 8.8) 
2.2 (1.2 – 
5.5) 
0.04 0.44 
HCO3 (mean ± SD) 13.1 ±6.94 10.83 
±5.71 
15.77 
±7.54 
13.65 ± 
5.20 
12.96 ± 
7.25 
0.06 0.86 
Base deficit (mean ± 
SD) 
15.42 
±9.03 
18.62 
±7.81 
11.59 
±9.27 
15.25 
±6.96 
15.45 ± 
9.42 
0.04 0.97 
pO2 (median [IQR]) 7.79 (4.75 
– 20.7) 
7.67 (4.8 – 
24.5) 
7.6 (4.5 – 
17.6) 
7.9 (7.67 – 
16.9) 
7.2 (4.5 – 
21.8) 
0.62 0.60 
pCO2 (mean ± SD) 3.88 ±1.87 3.76 ±1.97 4.18 ±1.75 3.59 ± 2.45 3.93 ± 1.79 0.53 0.71 
pH (mean ± SD) 7.17± 0.19 7.09 ±0.21 7.26 ±0.14 7.14 ±0.25 7.18 ±0.19  0.02 0.67 
Vitals: SaO2 (%) 
(median [IQR]) 
100 (98 – 
100) 
100.0 (98 – 
100) 
100.0 (100 
– 100) 
95.0 (95 – 
99) 
100 (100 – 
100) 
0.46 0.03 
BP (mean ± SD) 93.88 
±15.63 
94.23 
±13.12 
94.36 
±19.23 
92.0 
±22.35 
94.24 ± 
14.85 
0.98 0.80 
RR (mean ± SD) 47.33 ± 
16.38 
46.65 
±17.64 
47.46 
±15.72 
38.0 
±24.97 
49.12 
±14.19 
0.90 0.17 
HR (mean ± SD) 156.26 
±26.37 
152.88 
±23.95 
161.77 
±30.13 
137.0 
±18.52 
159.96 ± 
26.29 
0.38 0.07 
Temp (° C) (mean ± 
SD) 
36.12 ± 
1.68 
35.31 ± 
1.57 
37.11 
±1.33 
35.14 
±1.45 
36.30 ± 
1.68 
0.002 0.16 
Duration of hospital 
stay (days) 
11.50 (6.0 
– 17.5) 
12.0 (6 – 
25) 
10.5 (6.0 – 
16.0) 
14.0 (12 – 
23) 
8.0 (6 – 
17) 
0.50 0.12 
Length of ICU stay 
(days) (n=17) 
 3.0 (2.0 – 
7.0) 
_ 8 (3 – 9) 2 (1 – 4) _ 0.02 
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3. APPENDICES 
 
The Protocol 
Indication for and outcomes of continuous Positive Airways Pressure (CPAP) and 
High Flow Nasal Cannula oxygen therapy (HFNC) in children admitted to Red 
Cross War Memorial Children’s Hospital (RCWMCH) excluding those with 
primary respiratory aetiologies. 
 
Investigator:  Kate Browde 
Supervisors:  A/Prof Brenda Morrow 
  A/Prof Mignon McCulloch  
 
Introduction: 
 
Continuous positive airway pressure (CPAP) 
Noninvasive Continuous Positive Airway Pressure (nCPAP) is a mode of 
noninvasive ventilation where a preset positive pressure is provided 
continuously, either nasally or via a facemask or mouthpiece(1). 
 
Continuous Positive Airway Pressure (CPAP) was initially developed by Dr. 
George Gregory for use in premature infants with Hyaline Membrane Disease 
(HMD) in the early 1970’s (2). At that time, the mortality rate for infants with 
HMD was over 50%. During this period Harrison et al, a group of South African 
researchers, published their findings that grunting seemed to help infants with 
HMD to maintain higher saturation levels(3). These researchers monitored 
babies who were grunting and noted that their condition worsened after tracheal 
intubation, and improved again once they were extubated and allowed to resume 
grunting. The conclusion was drawn that by performing the modified valsalva 
manoeuvre of grunting, the babies were able to maintain their functional 
residual capacity and improve alveolar ventilation. Dr. Gregory used this 
information and devised a method of providing positive pressure via an 
endotracheal tube.  
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Measurable effects of CPAP include increased functional residual capacity, de-
creased intrapulmonary shunting, increased tidal volume and decreased airway 
resistance(4). Gregory managed to create these effects with his initial CPAP 
device: an endotracheal tube connected to an Ayres T-piece, which was 
connected to a gas inflow line. Fresh gas was introduced into the system near 
this T-piece, which was connected via corrugate tubing to a reservoir bag. The 
pressure in the system could be adjusted by varying inflow of gas or the degree 
of occlusion at the tail end of the reservoir bag.  
 
There are now numerous delivery systems for nasal CPAP, some of which are 
straightforward and relatively inexpensive(5). One of these is Bubble CPAP 
where the positive pressure is achieved by keeping the efferent limb of the 
exhale tubing under water and the gas flow adjusted to maintain constant 
bubbling. The depth of the exhale tubing under water determines the amount of 
CPAP applied to the system(6). Certain centres in resource-limited countries are 
developing their own bubble CPAP devices, sometimes using materials such as 
recycled plastic bottles, making the devices extremely affordable and yet still 
effective. A study was done in Malawi by Brown et al. (5) which showed that a 
stand-alone bubble CPAP device could be developed for one fifteenth of the price 
of the device recently approved by the FDA.  
 
With the use of CPAP, the mortality rate of infants with HMD has dramatically 
declined and CPAP is being used as one of the lung-protective strategies to 
prevent long term lung damage in preterm infants (7). CPAP has also been 
shown to be effective in the management of older children with Bronchiolitis and 
other respiratory illnesses(8–11) and has become a mainstay of treatment for 
many of these conditions. Being so effective and cheap to administer, CPAP 
represents a very important development in child health care in the developing 
world. 
 
High flow nasal cannula oxygen therapy  (HFNC) 
Heated, humidified, high flow nasal cannula oxygen therapy (HFNC) is a 
relatively new therapy first described in the early 1990’s (12). It allows the 
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delivery of inspired gas at higher flow rates than regular cannulae (1-8 L/min in 
infants).  The mechanisms of action of HFNC have the following benefits: flushing 
of dead space of the nasopharyngeal cavity allowing for better ventilation and 
oxygenation, providing high enough flow adequate to support inspiration and 
reducing inspiratory work of breathing, and eliminating the effects of drying and 
cooling(13). The fraction of inspired oxygen (FiO2) can be adjusted according to 
the patient’s needs and it can also provide some level of CPAP, although the exact 
level cannot always be predicted. 
 
HFNC is being used more and more commonly in neonatal units, either as a step-
down measure from CPAP or as an alternative measure in the management of 
HMD. The benefits of HFNC are that it is less cumbersome than CPAP, more 
easily applied, and causes less nasal trauma. In terms of efficacy, studies have 
shown no increase in adverse outcomes when replacing CPAP with HFNC in the 
management of HMD(12,14). 
 
HFNC is also being used more frequently in older children and has been shown 
to be as effective as CPAP in the management of bronchiolitis and other 
respiratory disorders. In a recent study by Metge et al (15) , HFNC was compared 
with nCPAP in infants admitted to PICU with severe acute bronchiolitis for two 
subsequent seasons.  Infants with acute bronchiolitis, and one or more of the 
following, were eligible for inclusion in the study: oxygen requirement to 
maintain oxygen saturations more than 92%, hypercarbia, acidosis and apnoea. 
They observed no difference in the length of stay in the PICU, respiratory rate, 
PCO2, FiO2, and duration of oxygen support between the two groups. 
 
Current practice 
At Red Cross War Memorial Children’s Hospital (RCWMCH), CPAP and HFNC are 
used commonly for respiratory conditions. There are guidelines issued by the 
pulmonology department about how and when each should be used. A stand-
alone Bubble-CPAP device is used. Unless a child needs to be intubated 
emergently, CPAP or HFNC are used as the mainstay of treatment for children 
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presenting in respiratory distress, especially those with high respiratory rates, 
severe signs of distress or respiratory acidosis on blood gas measurements. 
 
During the time spent in the Emergency Department of RCWMCH, it became 
obvious that CPAP and HFNC are being used in the management of children with 
respiratory compromise related to multiple aetiologies, not limited to primary 
respiratory aetiology, which remains the primary indication for their use. A large 
proportion of patients presenting to our emergency department in the summer 
months have gastroenteritis and dehydration as their presenting complaints 
with respiratory compromise occurring as a consequence of shock, 
hypokalaemia or severe metabolic acidosis that are associated with these 
conditions. We noted that CPAP and HFNC are being used very commonly in 
these patients as respiratory support, sometimes even as prophylactic measures 
when blood results or blood gases were suggestive of, for example, severe 
hypokalaemia or metabolic acidosis with respiratory compensation. Respiratory 
compromise might also occur in the face of septic shock or overwhelming sepsis. 
CPAP and HFNC are also often used in these conditions in our emergency unit.  
 
In their article “Approach to a Child with Breathing Difficulty”, Mathew et al (16), 
include sepsis (resulting in poor oxygenation of tissues with increased oxygen 
demand) and acidosis (with respiratory compensation) in the category titled 
“other” when describing the main physiological causes of respiratory distress in 
children. Although CPAP and HFNC have been found to be beneficial in the 
management and prevention of lung injury in preterm infants with respiratory 
distress (7); and in older children with bronchiolitis and other respiratory 
diseases (11,17–19); the evidence for the use of CPAP and HFNC in non-
respiratory conditions is scarce.  
 
In the 2012 guidelines for treating sepsis and septic shock published in the 
Journal of Intensive Care Medicine titled: “Surviving Sepsis Campaign: 
International Guidelines for Management of Severe Sepsis and Septic Shock, 
2012”, there is a section dedicated to paediatric considerations(20). The use of 
CPAP or HFNC is suggested in the initial resuscitation of children with 
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respiratory compromise or hypoxaemia associated with sepsis or septic shock. 
The authors describe how young children commonly need early respiratory 
support in circumstances of severe sepsis/septic shock because of their low 
functional residual capacity but that intubation and ventilation might actually be 
deleterious in these settings because increased intrathoracic pressure can lead to 
compromised venous return and worsening shock. They mention how HFNC and 
CPAP can be used to increase functional residual capacity and reduce the work of 
breathing, allowing for establishment of intravenous or intraosseous access for 
fluid resuscitation and peripheral inotrope delivery. They may also allow for the 
avoidance of drugs needed for sedation prior to intubation, which may also be 
counterintuitive in the setting of sepsis, shock, hypokalaemia or hypovolaemia. 
 
Despite this recommendation, we could only identify one article in which the use 
of CPAP is specifically studied in the context of septic shock syndrome.  Cam et al 
compared the use of oxygen mask therapy with nasal CPAP in the management 
of children with respiratory failure associated with Dengue Haemorrhagic Fever 
(DHF) grades 3-4, termed Dengue Shock Syndrome (DSS)(21).  The aetiology of 
the respiratory failure in DSS may be due to increased vascular permeability 
leading to alveolar oedema, fluid overload, pleural and peritoneal effusions, 
acute respiratory distress syndrome (ARDS) or cardiac failure. They found that 
nCPAP was useful in the management of these patients. 
 
With this in mind we plan to investigate the use of HFNC and CPAP in the 
emergency department, high care wards and Paediatric intensive care unit 
(PICU) at RCWMCH. 
 
Aims and objectives: 
To describe the indications for and outcomes of non-respiratory uses for CPAP 
and HFNC in children admitted to RCWMCH. 
 
Setting: 
Red Cross War Memorial Children’s Hospital (RCWMCH) is a public tertiary and 
secondary level hospital in Cape Town, South Africa. It is the only stand alone, 
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specialist children’s hospital dedicated entirely to paediatric care in southern 
Africa. RCWMCH has a total of 275 beds (medical and surgical) of which 15 are 
“High Care” medical beds and 22 are in the PICU. Currently, children on CPAP 
and HFNC can only be managed in high care or PICU due to nursing constraints. 
 
An average of 40 000 children per year are seen at RCWMCH, with a large 
proportion of emergency admissions to the High Care units and PICU coming via 
the medical emergency unit (MEU). It is estimated that 360 urgent admissions to 
PICU and 1200 to the high care units are admitted via the MEU. 
 
Because of the highly specialised care available at RCWMCH a wide variety of 
illnesses are seen and children are referred from all over the country, but the 
majority of patients are admitted with acute infections-generally either 
respiratory or gastrointestinal, depending on the season. For example, in 2013, 
7599 children were admitted to the short stay ward at RCWMCH. 2997 of those 
presented with acute respiratory infections and 1803 presented with acute 
gastroenteritis. A similar proportion would have been admitted to higher care 
settings.  
 
Methods: 
Study design: Prospective observational study.Duration : 6 months or 100 
consecutive patients.  
 
Participants: 
Inclusion criteria: 
Any child admitted to RCWMCW with a clinical diagnosis other than a primary 
respiratory pathology, receiving CPAP or HFNC as part of standard clinical 
management. 
 
Exclusion criteria 
 Children receiving CPAP/HFNC for complications of bronchiolitis,asthma, 
or a primary clinical diagnosis of pneumonia or other primary respiratory 
illnesses 
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 Neonates 
 Children receiving home-based CPAP/HFNC for the management of 
chronic respiratory conditions  
 Cardiogenic pulmonary oedema 
 Children receiving CPAP/HFNC for the management of sleep apnoea. 
 
Data collection and research procedures: 
MEU admissions will be reviewed daily by researcher to identify eligible patients 
and patients receiving CPAP/HFNC therapy in the medical wards or PICU will be 
screened for eligibility daily by same researcher. 
Admission data will be prospectively collected from patient clinical folders on all 
eligible patients, using a standardised data collection form (Appendix A) and 
outcome data will be collected at discharge or after death from hospital records, 
the PICU database and Clinicom. 
 
The data to be collected for study purposes is routinely documented as standard 
of care for all patients so will be available in their files and clinical records. 
 
Since the study participants’ files will only be reviewed for outcome data after 
discharge or death, there will be little chance of identifying clinical omissions or 
errors while the patient is still admitted. However should these be identified by 
the investigator at any stage, the relevant ward consultant would be alerted. 
 
Outcome measures:   
Number of patients receiving CPAP/HFNC for non-respiratory illnesses, 
proportion of patients admitted to PICU, proportion of patients intubated and 
invasively ventilated, duration of hospital and PICU length of stay, and mortality. 
Failure of CPAP or HFNC will be considered for patients who are intubated and 
ventilated invasively. 
 
Ethical considerations, Risks and benefits: 
No intervention will be conducted as part of this study, which is purely 
observational in recording outcomes of current standard practice.  
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It is therefore considered that this study affords minimal risk to participants. 
Participant protection will be ensured by de-identifying all data (using codes 
instead of names), and password-protecting the database, which will only be 
accessible by the investigators. No identification of any participants will occur on 
any output arising from this research. 
 
Despite this, in order to maintain respect for person and autonomy, we will 
obtain written informed consent from parents to inform them about the study 
being conducted and to request their consent to use information obtained from 
their child’s files (Appendix B). The consent form will assure them of the 
anonymity and privacy afforded to them by de-identification of the patient and 
use of a password-protected database. 
The consent form will be available in English, isiXhosa and Afrikaans, and 
consent will be taken in the language of choice, with the use of interpreters 
where necessary. 
 
Permission to conduct the study will be obtained from the University of Cape 
Town’s Faculty of Health Sciences Human Research Ethics Committee and 
research will adhere to the provisions of the Declaration of Helsinki (2013). 
 
Reimbursement: 
Will not be offered to study participants. 
 
Analysis 
Data will be entered into an Excel spreadsheet and appropriate parametric or 
nonparametric descriptive analyses will be conducted using Statistica version 11 
(StaSoft Inc, Tulsa, USA), after testing for normality (Shapiro Wilks W test). 
Comparative statistics will be conducted (Mann-whitney U or T-tests according 
to distribution) using failure of CPAP/HFNC and mortality as categorical 
outcome measures. Data found to be associated with these outcomes on 
univariate analysis (p < 0.05) will be entered into a forward stepwise logistic 
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regression model to determine independent predictive factors. A significance 
level of p< 0.05 will be used for this study. 
 
Conflicts of interest: 
None to declare 
 
Limitations: 
Since there is only one researcher collecting data and patients might be started 
on CPAP/HFNC at any time in numerous different places, patients might be 
missed. 
Since there might be both respiratory and non-respiratory pathology in certain 
patients, data might be difficult to interpret in these cases. 
This is an observational study without a control group, and therefore we will not 
be able to determine cause and effect related to outcomes. It will, however, form 
the basis for future prospective interventive studies. 
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Appendix A 
 
Data collection form 
 
1 Folder Number: 
 
2. Identifier code:  
 
3. DOB: 
 
4 Age and sex 
 
5. Date of admission: 
 
6. Date of discharge: 
 
7. Date of death: 
 
8. Primary presenting complaint: 
 
9.Main Presenting signs: 
1. 
2. 
3. 
 
10. Vital signs: 
Temp: 
HR: 
RR: 
BP: 
Sats: 
 
11. Shocked? 
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Yes 
No 
 
12. Gas done 
Yes 
No 
 
13. First Gas result: 
pH: 
pCO2: 
pO2: 
BE: 
HCO3: 
Lactate: 
Sats: 
 
14. Blood results on presentation: 
Na: 
K: 
Cl: 
Urea : 
Creatinine: 
 
WCC: 
Hb: 
Platelets: 
Other: 
 
15. CPAP or HFNC 
 
16. Reason documented for initiating respiratory support: 
 
17.Fluid boluses: 
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Yes 
No 
 
18. Inotropes: 
yes 
No 
 
19. Admitted to: 
High Care 
ICU 
Other 
 
20.  Subsequent gases: 
1.Date  
Time         
pH 
pCO2 
pO2 
BE 
HCO3 
Lactate 
Sats 
 
2.Date 
Time         
pH 
pCO2 
pO2 
BE 
HCO3 
Lactate 
Sats 
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3.Date 
Time         
pH 
pCO2 
pO2 
BE 
HCO3 
Lactate 
Sats 
 
21. Subsequent relevant blood results: 
 
22. Culture results: 
Blood: 
NPA: 
CSF: 
 
23. Complications: 
 
24. Required intubation? 
Yes 
no 
 
25. Length of ICU stay 
 
26. Length of hospital stay 
 
27. Mortality 
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Appendix B 
INFORMED CONSENT FORM FOR THE PARENT(S)/GUARDIAN(S) OF CHILDREN 
RECEIVING RESPIRATORY SUPPORT WITH CPAP/HFNC FOR NON-RESPIRATORY 
INDICATIONS. 
This Informed Consent Form has two parts: 
 Part I: Information Sheet (to share information about the study with you) 
 Part II: Certificate of Consent (for signatures if you agree that your child 
may participate) 
You will be given a copy of the full Informed Consent Form. 
PART I: Information sheet 
I, Dr. Kate Browde (MMED- student at the University of Cape Town), am doing 
research on devices that help children with breathing problems. The study is 
called “Indication for and outcomes of continuous Positive Airways Pressure 
(CPAP) and High Flow Nasal Cannula oxygen therapy (HFNC) in children 
admitted to Red Cross War Memorial Children’s Hospital (RCWMCH), excluding 
those with primary respiratory aetiologies”. 
We would like to invite your child to participate in this study, by allowing us to 
use medical information about your child and his/her illness. Before you decide 
whether you are happy for us to use this information, please read the following 
information, which we will also explain and discuss. Please feel free to ask 
questions about anything you do not fully understand. 
What is the reason for the study and how will it be done? 
Children often struggle to breathe when they become very sick. Breathing 
problems are not only caused by infections or illnesses in the lungs. We want to 
find out how many children need breathing support for other reasons, for 
example, extreme fatigue (tiredness), severe infections, organ failure, electrolyte 
abnormalities etc. 
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With the information we obtain from this study, we can encourage further 
research on the topic and inform doctors in other hospitals on how best to use 
this type of respiratory support for other sick children. 
The study will be done by identifying children who require breathing support for 
illnesses that are not only in their lungs. We will later look at the files of these 
children and see how they progress, what other interventions were necessary for 
them and how long they stay in hospital. 
What does the study mean for your child? 
The study will take place during the time your child is in the hospital. While your 
child is hospitalised at Red Cross War Memorial Children’s Hospital, he/she will 
receive standard care. This means that there will be no change in the care your 
child will receive if you agree to participate in the study-he/she will be treated 
the same as all other patients. 
What are the possible benefits and/or risks to your child? 
There are no direct benefits to participate in the study. 
Potential harms – there are no major harms expected other than a possible 
breach of confientiality. However, we will strive to avoid this by using numbers 
instead of names and having passwords for all our databases. 
Voluntary participation 
Your decision to have your child participate in this study is entirely voluntary. It 
is your choice whether to have your child participate or not. If you choose not to 
consent, it will in no way affect the care your child received at red Cross.  
Confidentiality 
The information that we collect from this research project will be kept 
confidential. Any information about your child will have a number on it instead 
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of his/her name. Only the investigators will know what information belongs to 
your child.  
Payment for involvement 
Participation in this research does not involve extra costs for you, and you will 
not receive payment if you agree to your child being enrolled. 
Contact details 
If you have any questions or worries after reading this form or at any other time 
during or after the study, please do not hesitate to contact us. You may contact 
the University of Cape Town Faculty of Health Sciences Human Ethics Committee 
(HREC) if you have any questions or concerns regarding your child’s rights or 
welfare as a research participant.  
Dr Kate Browde  
021 658 5111 
kbrowde@gmail.com 
     
Prof Brenda Morrow 
021 658 5074      
brenda.morrow@uct.ac.za 
  
Prof Mignon McCulloch 
021 658 5354 
mignon.mcculloch@uct.ac.za 
 
Human Research Ethic Committee (HREC)  
Prof Marc Blockman, Chair   
Old Main Building, Groote Schuur Hospital    
021 406 6338  
Marc.Blockman@uct.ac.za 
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PART II: Certificate of consent 
If you agree to us using your child’s information for this research study, we ask 
you to sign this staement of consent: 
I have read the above information, and it has been fully explained to me. I 
have had the opportunity to ask questions about it and any questions that I 
have asked have been answered to my satisfaction. I consent voluntarily 
for my child to participate as a participant in this study. 
 
Print Name of Participant__________________  
Print Name of Parent or Guardian_______________     
Signature of Parent or Guardian ___________________ 
Date ___________________________ 
Witness (in the case of the parent being unable to read/sign)____________________ 
 
Date__________________________ 
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Manuscripts should be written so that they are intelligible to the professional 
reader who is not a specialist in the particular field. Where contributions are 
judged as acceptable for publication on the basis of scientific content, the Editors 
or the Publisher reserve the right to modify typescripts to eliminate ambiguity 
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at http://exchanges.wiley.com/authors/faqs---copyright-terms--
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MANUSCRIPT CATEGORIES 
Annotations 
Annotations should be no more than 1500 words with a maximum of 12 
references. Authors must supply a maximum of 5 key words and an unstructured 
abstract. Authors must supply three brief 'Key Points' summarising the main 
points raised in the manuscript. Authors must also provide 3 multiple choice 
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explanations for each answer) based on their Annotation. Please ensure that 
brief explanations are provided for both correct and incorrect answers. 
Editorial Comments 
Editorial Comments should be no more than 1500 words with a maximum of 12 
references. Authors must supply a one-line summary of the key point raised and 
provide a reference to the manuscript(s) the paper comments on. 
Original Articles 
Original Articles should be no more than 2500 words with a structured abstract 
that states in 250 words or fewer the purpose, basic procedures, main findings 
and principal conclusions of the study. Divide the abstract with the headings: 
Aim, Methods, Results, Conclusions. Authors must supply up to three brief points 
'What is already known on this topic' and up to three brief points stating 'What 
this paper adds'. 
Review Article 
Review Articles should be no more than 2500 words with a maximum of 50 
references. Abstracts can be either structured or unstructured, at a maximum of 
150 words. The abstract should not contain abbreviations or references. Authors 
must supply three brief 'Key Points' summarising the main points raised in the 
manuscript. Authors must also provide 3 multiple choice questions (preferably 
'A-type' single best of 5 alternatives with brief explanations for each answer) 
based on their Review. Please ensure that brief explanations are provided for 
both correct and incorrect answers. 
Case Reports 
The Journal of Paediatrics and Child Health has amended its Case Report section. 
New Case Notes/Reports will now only be considered for publication in the 
Letters to the Editor section. In order to suit this format, manuscripts need to be 
formatted as a Letter to the Editor and be approximately 400 words in length, 
with no more than one figure or table, and a maximum of four references. 
Clinical Trials 
Clinical Trials must be registered with the appropriate governing body. 
Instructive Cases 
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There is an initial case report, then a brief discussion with appropriate 
references. No abstract or key words are required (when the website requests an 
Abstract, type N/A for 'not applicable'). A Summary listing learning points should 
be included at the end of the Instructive Case. Instructive Cases should be no 
more than 1200 words in length, with no more than 3 figures or tables and a 
maximum of 8 references. Authors must also provide 3 multiple choice questions 
(preferably 'A-type' single best of 5 alternatives with brief explanations for each 
answer) based on their Instructive Case. Please ensure that brief explanations 
are provided for both correct and incorrect answers. 
Letters to the Editor 
Letters to the Editor should be no more than 400 words in length, with no more 
than one figure or table, and a maximum of four references. 
Heads Up 
Heads Up submissions should be a summary, approximately 200 words, of a 
recent paper of interest. This should not be the abstract but a short digest of the 
results, putting them in context of what the paper adds. Please attach a file with a 
single graph or histogram (preferably not a table) from the paper to make the 
most important point visually (not essential). A photograph or illustration 
(subject to copyright) would also be suitable. The names of authors of Heads Up 
pieces will be published. 
Journal Club 
Journal club articles should be no more than 2500 words. They should reflect 
what happens at journal clubs where doctors come with a clinical question, 
search for evidence, critically appraise the best evidence and then apply it to 
their patient, reflecting how the research could have been conducted better. The 
paper should be divided into the headings: Clinical scenario, Structured clinical 
question, Search strategy, Table (of relevant papers found in the search), Critical 
appraisal of all relevant papers (using standard critical appraisal guidelines), 
followed by a brief discussion of how to do the research better, how to apply the 
information to the patient and the clinical bottom line. 
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Image of the Month 
Please send a photograph or other image, together with a short clinical question 
and a brief answer. For an example, please follow these 
links: Question and Answer. If the photograph is identifiable, please send written 
permission from a parent and/or child or confirm that verbal approval has been 
obtained. Privacy is the responsibility of the author(s). 
Position Papers 
Position Papers express the consenses view of an organisation, e.g. about the 
management of a condition. Any recommendations should be evidence-based 
and should state the Level of Evidence (using NHMRC criteria). They should be 
up to 2,500 words long with a maximum of 50 references. 
Viewpoint 
Viewpoint is available for papers expressing a personal practice or personal view 
on medical or non-medical topics that are relevant to the readers. They can be up 
to 2,500 words long and referenced if appropriate. 
Ethical Debate 
Ethical debate is available for papers describing an ethical dilemma in clinical 
practice. They may argue only one perspective or two different viewpoints. They 
can be up to 2,500 words long and reference if appropriate. 
Brief Communications 
Brief Communications are used to fill gaps in the JPCH and will be indexed. They 
are supposed to be entertaining, humorous, informative, thought-provoking or 
all of the above. They should be relevant, in a broad sense, to paediatrics and 
those who work in child health. They should be no longer than 600 words. 
Examples include humorous or poignant stories or instructive mistakes. Consent 
will be needed if the subject of the Brief Communication is identifiable. 
Fillers 
FIllers are used to fill gaps in the JPCH, but are not indexed. They are supposed to 
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be entertaining, humorous, informative, thought-provoking or all of the above. 
Examples of Fillers include cartoons and poems. Consent will be needed if the 
subject of the Filler is identifiable. 
 
PREPARATION OF MANUSCRIPTS 
Pre-acceptance English-language editing 
Authors for whom English is a second language may choose to have their 
manuscript professionally edited before submission to improve the English. Visit 
our site to learn about the options. All services are paid for and arranged by the 
author.  Please note using the Wiley English Language Editing Service does not 
guarantee that your paper will be accepted by this journal. 
Video Abstracts 
A video abstract can be a quick way to make the message of your research 
accessible to a much larger audience. Wiley and its partner Research Square 
offer a service of professionally produced video abstracts, available to authors of 
articles accepted in this journal. You can learn more about it, and purchase one 
for your article, at https://www.wileuauthors.com/videoabstracts. If you have 
any questions, please direct them to videoabstracts@wiley.com . 
Optimising Your Article for Search Engines 
Many students and researchers looking for information online will use search 
engines such as Google, Yahoo or similar. By optimising your article for search 
engines, you will increase the chance of someone finding it. This in turn will 
make it more likely to be viewed and/or cited in another work. We have 
compiled these guidelines to enable you to maximise the web-friendliness of the 
most public part of your article. 
Style of the Manuscript 
Manuscripts should follow the style of the Vancouver agreement detailed in the 
International Comittee of Medical Journal Editors' revised 'Uniform 
Requirements for Manuscripts Submitted to Biomedical Journals: Writing and 
Editing for Biomedical Publication', as presented at http://www.ICMJE.org 
Spelling 
The journal uses UK spelling and authors should therefore follow the latest 
edition of the Concise Oxford Dictionary. 
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Units 
All measurements must be given in SI units. 
 
Abbreviations 
Abbreviations should be used sparingly and only where they ease the reader’s 
task by reducing repetition of long, technical terms. Initially use the word in full, 
followed by the abbreviation in parentheses. Thereafter use the abbreviation. 
 
Scientific names 
Upon its first use in the title, abstract and text, the common name of a species 
should be followed by the scientific name (Genus, species and authority) in 
parentheses. However, for well-known species, the scientific name may be 
omitted from the article title. If no common name exists in English, the scientific 
name should be used only. 
 
Trade names 
At the first mention of a chemical substance, give the generic name only. Trade 
names should not used. 
Drugs should be referred to by their generic names, rather than brand names. 
 
Equations 
Equations should be numbered sequentially with Arabic numerals; these should 
be ranged right in parentheses. All variables should appear in italics. Use the 
simplest possible form for all mathematical symbols. 
 
Parts of the Manuscript 
The manuscript should be submitted in separate files: title page; main text file; 
figures. 
 
Title page 
The title page should contain (i) a short informative title that contains the major 
key words. The title should not contain abbreviations (ii) the type of manuscript 
(e.g. Original Article, Instructive Case, Editorial Correspondence: Case Note), (iii) 
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the full names of the authors and (iv) the addresses of the institutions at which 
the work was carried out together with (v) the full postal and email address, plus 
telephone numbers, of the author to whom correspondence about the 
manuscript, proofs and requests for offprints should be sent. The present 
address of any author, if different from that where the work was carried out, 
should be supplied in a footnote. 
Main text 
As papers are double-blind peer reviewed the main text file should not include 
any information that might identify the authors. The main text of the manuscript 
should be presented in the following order: (i) abstract and key words, (ii) text, 
(iii) acknowledgements (iv) references, (v) tables (each table complete with title 
and footnotes), (vi) figure legends. Figures and supporting information should be 
submitted as separate files. Footnotes to the text are not allowed and any such 
material should be incorporated into the text as parenthetical matter. 
Abstract and Key words 
Please refer to the section 'Manuscript Categories' for details about which article 
types require abstracts. Key words should be taken from those recommended by 
the US National Library of Medicine's Medical Subject Headings (MeSH) browser 
list. 
Text 
Authors should use subheadings to divide the sections of their manuscript: 
Introduction, Materials and Methods, Results, Discussion. 
Acknowledgements 
The source of financial grants and other funding should be acknowledged, 
including a frank declaration of the authors’ industrial links and affiliations. The 
contribution of colleagues or institutions should also be acknowledged. Thanks 
to anonymous reviewers are not allowed. 
References 
The Vancouver system of referencing should be used. In the text, references 
should be cited using superscript Arabic numerals in the order in which they 
appear. If cited only in tables or figure legends, number them according to the 
first identification of the table or figure in the text. In the reference list, the 
references should be numbered and listed in order of appearance in the text. 
 76 
 
Cite the names of all authors when there are six or fewer; when there are seven 
or more list the first three followed by et al. 
Names of journals should be abbreviated in the style used in Index Medicus. 
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in the list but should be cited in the text only (e.g. A Smith, unpubl. data, 2000). 
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Appendices 
These should be placed at the end of the paper, numbered in Roman numerals 
and referred to in the text. If written by a person other than the author of the 
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main text, the writer’s name should be included below the title. 
 
Tables 
Tables should be self-contained and complement, but not duplicate, information 
contained in the text. Tables should be numbered consecutively in Arabic 
numerals. Each table should be presented on a separate sheet of A4 paper with a 
comprehensive but concise legend above the table. Tables should be double-
spaced and vertical lines should not be used to separate columns. Column 
headings should be brief, with units of measurement in parentheses; all 
abbreviations should be defined in footnotes. Footnote symbols: †, ‡, §, ¶ should 
be used (in that order) and *, **, *** should be reserved for P-values. Statistical 
measures such as SD or SEM should be identified in the headings. The table and 
its legend/footnotes should be understandable without reference to the text. 
 
Figure legends 
Legends should be self-explanatory and typed on a separate page. The legend 
should incorporate definitions of any symbols used and all abbreviations and 
units of measurement should be explained so that the figure and its legend are 
understandable without reference to the text. 
Figures 
All illustrations (line drawings and photographs) are classified as figures. Figures 
should be cited in consecutive order in the text. Figures should be sized to fit 
within the column (80 mm), intermediate (121 mm) or the full text width (169 
mm). Magnifications should be indicated using a scale bar on the illustration. 
Preparation of Electronic Figures for Publication: Although low quality images are 
adequate for review purposes, print publication requires high quality images to 
prevent the final product being blurred or fuzzy. Submit EPS (line art) or TIFF 
(halftone/photographs) files only. MS PowerPoint and Word Graphics are 
unsuitable for printed pictures. Do not use pixel-oriented programmes. Scans 
(TIFF only) should have a resolution of 300 dpi (halftone) or 600 to 1200 dpi 
(line drawings) in relation to the reproduction size (see below). EPS files should 
be saved with fonts embedded (and with a TIFF preview if possible). For scanned 
images, the scanning resolution (at final image size) should be as follows to 
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ensure good reproduction: line art: >600 dpi; half-tones (including gel 
photographs): >300 dpi; figures containing both halftone and line images: >600 
dpi. 
More advice on figures can be found at Wiley’s guidelines for preparation of 
figures: http://authorservices.wiley.com/bauthor/illustration.asp 
 
SUBMISSION REQUIREMENTS 
A cover letter may be submitted if you wish via the ‘Cover Letter Field’ of the 
ScholarOne system. The text can be entered directly into the field or uploaded as 
a file. 
Two Word-files need to be included upon submission: A title page file and a main 
text file that includes all parts of the text in the sequence indicated in the section 
'Parts of the manuscript', including tables and figure legends but excluding 
figures which should be supplied separately. 
The main text file should be prepared using Microsoft Word, using 1.5 line 
spacing. All pages should be numbered consecutively in the top right-hand 
corner, beginning with the first page of the main text file. 
Each figure should be supplied as a separate file, with the figure number 
incorporated in the file name. For submission, low-resolution figures saved as 
.jpg or .bmp files should be uploaded, for ease of transmission during the review 
process. Upon acceptance of the article, high-resolution figures (at least 300 
d.p.i.) saved as .eps or .tif files will be required. 
PUBLICATION PROCESS AFTER ACCEPTANCE 
Accepted papers will be passed to Wiley’s production team for publication. The 
author identified as the formal corresponding author for the paper will receive 
an email prompting them to login into Wiley’s Author Services, where via the 
Wiley Author Licensing Service (WALS) they will be asked to complete an 
electronic license agreement on behalf of all authors on the paper. More details 
on the copyright and licencing options for the journal appear below. 
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Wiley’s Author Services 
Author Services enables authors to track their article through the production 
process to publication online and in print. Authors can check the status of their 
articles online and choose to receive automated e-mails at key stages of 
production. The corresponding author will receive a unique link that enables 
them to register and have their article automatically added to the system. 
Visithttp://www.authorservices.wiley.com/bauthor/eachecklist.asp for more 
details on online production tracking and for a wealth of resources including 
FAQs and tips on article preparation, submission and more. 
Proofs 
It is essential that corresponding authors supply an email address to which 
correspondence can be emailed while their article is in production. 
Notification of the URL from where to download a Portable Document Format 
(PDF) typeset page proof, associated forms and further instructions will be sent 
by email to the corresponding author. 
The purpose of the PDF proof is a final check of the layout, and of tables and 
figures. Alterations other than the essential correction of errors are unacceptable 
at PDF proof stage. The proof should be checked, and approval to publish the 
article should be emailed to the Publisher by the date indicated in order not to 
delay prompt publication. 
Early View 
The journal offers rapid speed to publication via Wiley’s Early View service. 
Early View articles are complete full-text articles published online in advance of 
their publication in a printed issue. Early View articles are complete and final. 
They have been fully reviewed, revised and edited for publication, and the 
authors' final corrections have been incorporated. Because they are in final form, 
no changes can be made after online publication. Early View articles are given a 
Digital Object Identifier (DOI), which allows the article to be cited and tracked 
before allocation to an issue. After print publication, the DOI remains valid and 
can continue to be used to cite and access the article. More information about 
DOIs can be found at http://www.doi.org/faq.html. 
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A PDF reprint of the article will be supplied free of charge to the corresponding 
author. Additional printed offprints may be ordered online for a fee. Please click 
on the following link and fill in the necessary details and ensure that you type 
information in all of the required fields: http://offprint.cosprinters.com/cos. If 
you have queries about offprints please e-mail: offprint@cosprinters.com. 
Author Marketing Toolkit 
The Wiley Author Marketing Toolkit provide authors with support on how to use 
social media, publicity, conferences, multimedia, email and the web to promote 
their article. 
Supporting Information 
Supporting information is hosted online separately to the article. This should be 
used for information that is not essential to the article but that provides greater 
depth and background. It may include tables, figures, videos, datasets, etc. This 
material can be submitted with your manuscript, and will appear online, without 
editing or typesetting. Guidelines on how to prepare this material and which 
formats and files sizes are acceptable can be found 
at: www.wileyauthors.com/suppinfo 
Please note that the provision of supporting information is not encouraged as a 
general rule. It will be assessed critically by reviewers and editors and will only 
be accepted if it is essential. 
COPYRIGHT, LICENSING AND ONLINE OPEN 
Accepted papers will be passed to Wiley’s production team for publication. The 
author identified as the formal corresponding author for the paper will receive 
an email prompting them to login into Wiley’s Author Services, where via the 
Wiley Author Licensing Service (WALS) they will be asked to complete an 
electronic license agreement on behalf of all authors on the paper. 
Authors may choose to publish under the terms of the journal’s standard 
copyright transfer agreement (CTA), or under open access terms made available 
via Wiley OnlineOpen. 
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Standard Copyright Transfer Agreement:  
FAQs about the terms and conditions of the standard CTA in place for the journal, 
including standard terms regarding archiving of the accepted version of the 
paper, are available at: Copyright Terms and Conditions FAQs. 
Note that in signing the journal’s licence agreement authors agree that consent 
to reproduce figures from another source has been obtained. 
OnlineOpen – Wiley’s Open Access Option:  
OnlineOpen is available to authors of articles who wish to make their article 
freely available to all on Wiley Online Library under a Creative Commons license. 
With OnlineOpen, the author, the author's funding agency, or the author's 
institution pays a fee to ensure that the article is made open access. Authors of 
OnlineOpen articles are permitted to post the final, published PDF of their article 
on their personal website, and in an institutional repository or other free public 
server immediately after publication. All OnlineOpen articles are treated in the 
same way as any other article. They go through the journal's standard peer-
review process and will be accepted or rejected based on their own merit. 
OnlineOpen licenses. Authors choosing OnlineOpen retain copyright in their 
article and have a choice of publishing under the following Creative Commons 
License terms: Creative Commons Attribution License (CC BY); Creative 
Commons Attribution Non-Commercial License (CC BY NC); Creative Commons 
Attribution Non-Commercial-NoDerivs License (CC BY NC ND). To preview the 
terms and conditions of these open access agreements please visit the Copyright 
Terms and Conditions FAQs. 
Funder Open Access and Self-Archiving Compliance:  
Please click here for more information on Wiley’s compliance with specific 
Funder Open Access and Self Archiving Policies, and click here for more detailed 
information specifically about Self-Archiving definitions and policies. 
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